Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IDIX's Cash to Debt is ranked higher than
84% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. IDIX: No Debt )
IDIX' s 10-Year Cash to Debt Range
Min: 2.47   Max: No Debt
Current: No Debt

Equity to Asset 0.77
IDIX's Equity to Asset is ranked higher than
81% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. IDIX: 0.77 )
IDIX' s 10-Year Equity to Asset Range
Min: -0.74   Max: 0.88
Current: 0.77

-0.74
0.88
Interest Coverage No Debt
IDIX's Interest Coverage is ranked higher than
94% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IDIX: No Debt )
IDIX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 41.37
M-Score: 67.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 550.02
IDIX's Operating margin (%) is ranked higher than
100% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. IDIX: 550.02 )
IDIX' s 10-Year Operating margin (%) Range
Min: -26379.53   Max: -8.59
Current: 550.02

-26379.53
-8.59
Net-margin (%) 545.06
IDIX's Net-margin (%) is ranked higher than
99% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. IDIX: 545.06 )
IDIX' s 10-Year Net-margin (%) Range
Min: -26073.99   Max: -6.55
Current: 545.06

-26073.99
-6.55
ROE (%) -109.36
IDIX's ROE (%) is ranked higher than
57% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. IDIX: -109.36 )
IDIX' s 10-Year ROE (%) Range
Min: -5602   Max: -15.36
Current: -109.36

-5602
-15.36
ROA (%) -86.85
IDIX's ROA (%) is ranked higher than
55% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. IDIX: -86.85 )
IDIX' s 10-Year ROA (%) Range
Min: -627.45   Max: -4.91
Current: -86.85

-627.45
-4.91
ROC (Joel Greenblatt) (%) -5826.62
IDIX's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. IDIX: -5826.62 )
IDIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5324.09   Max: -150.73
Current: -5826.62

-5324.09
-150.73
Revenue Growth (%) -100.00
IDIX's Revenue Growth (%) is ranked higher than
55% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. IDIX: -100.00 )
IDIX' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 235.2
Current: -100

-100
235.2
EBITDA Growth (%) 3.50
IDIX's EBITDA Growth (%) is ranked higher than
83% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. IDIX: 3.50 )
IDIX' s 10-Year EBITDA Growth (%) Range
Min: -69.4   Max: 105.7
Current: 3.5

-69.4
105.7
EPS Growth (%) 1.50
IDIX's EPS Growth (%) is ranked higher than
82% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. IDIX: 1.50 )
IDIX' s 10-Year EPS Growth (%) Range
Min: -77.4   Max: 114
Current: 1.5

-77.4
114
» IDIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

IDIX Guru Trades in Q3 2013

Seth Klarman 29,665,693 sh (+10.83%)
Chuck Royce 736,000 sh (unchged)
Jim Simons Sold Out
Jeremy Grantham 21,600 sh (-27.03%)
» More
Q4 2013

IDIX Guru Trades in Q4 2013

Steven Cohen 13,900 sh (New)
Jeremy Grantham 56,100 sh (+159.72%)
Seth Klarman 36,910,868 sh (+24.42%)
Chuck Royce 665,980 sh (-9.51%)
» More
Q1 2014

IDIX Guru Trades in Q1 2014

Steven Cohen 96,000 sh (+590.65%)
Seth Klarman 53,331,109 sh (+44.49%)
Jeremy Grantham Sold Out
Chuck Royce 534,316 sh (-19.77%)
» More
Q2 2014

IDIX Guru Trades in Q2 2014

Mario Gabelli 142,184 sh (New)
Prem Watsa 50,400 sh (New)
Seth Klarman 53,331,109 sh (unchged)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IDIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Prem Watsa 2014-06-30 New Buy0.08%$4.94 - $24.12 $ 24.5140%50400
Mario Gabelli 2014-06-30 New Buy0.02%$4.94 - $24.12 $ 24.5140%142184
Seth Klarman 2014-03-31 Add 44.49%2.25%$5.82 - $8.04 $ 24.5252%53331109
Seth Klarman 2013-12-31 Add 24.42%1.24%$3.29 - $6.93 $ 24.5433%36910868
Seth Klarman 2013-09-30 Add 10.83%0.43%$3.22 - $5.75 $ 24.5459%29665693
Seth Klarman 2013-03-31 Add 25.78%0.61%$3.54 - $5.36 $ 24.5433%26042000
John Burbank 2013-03-31 Sold Out 0.19%$3.54 - $5.36 $ 24.5433%0
Seth Klarman 2012-12-31 Add 72.54%1.35%$3.52 - $5.3 $ 24.5443%20704700
Jean-Marie Eveillard 2012-12-31 Sold Out 0.0025%$3.52 - $5.3 $ 24.5443%0
Seth Klarman 2012-09-30 Add 20%0.28%$4.39 - $11.06 $ 24.5210%12000000
Jean-Marie Eveillard 2012-09-30 New Buy$4.39 - $11.06 $ 24.5210%150000
Seth Klarman 2012-06-30 Add 21.23%0.47%$7.24 - $10.71 $ 24.5175%10000000
John Burbank 2012-06-30 Add 150%0.26%$7.24 - $10.71 $ 24.5175%1250000
Seth Klarman 2012-03-31 Add 45.61%0.85%$7.01 - $14.89 $ 24.5122%8249000
John Burbank 2012-03-31 New Buy0.17%$7.01 - $14.89 $ 24.5122%500000
George Soros 2012-03-31 Sold Out 0.08%$7.01 - $14.89 $ 24.5122%0
Seth Klarman 2011-12-31 Add 126.6%0.73%$4.55 - $8.22 $ 24.5278%5665000
George Soros 2011-12-31 Add 1382.72%0.08%$4.55 - $8.22 $ 24.5278%255028
Seth Klarman 2011-09-30 Add 99.09%0.21%$4.15 - $6.96 $ 24.5331%2500000
George Soros 2011-09-30 New Buy$4.15 - $6.96 $ 24.5331%17200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 24.26
IDIX's P/B is ranked higher than
59% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. IDIX: 24.26 )
IDIX' s 10-Year P/B Range
Min: 1.28   Max: 74.22
Current: 24.26

1.28
74.22
EV-to-EBIT -21.73
IDIX's EV-to-EBIT is ranked higher than
73% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IDIX: -21.73 )
IDIX' s 10-Year EV-to-EBIT Range
Min: 63.5   Max: 96.8
Current: -21.73

63.5
96.8
Current Ratio 6.59
IDIX's Current Ratio is ranked higher than
84% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. IDIX: 6.59 )
IDIX' s 10-Year Current Ratio Range
Min: 1.75   Max: 17.46
Current: 6.59

1.75
17.46
Quick Ratio 6.59
IDIX's Quick Ratio is ranked higher than
84% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. IDIX: 6.59 )
IDIX' s 10-Year Quick Ratio Range
Min: 1.75   Max: 17.46
Current: 6.59

1.75
17.46

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.84
IDIX's Price/Net Cash is ranked higher than
78% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 100.00 vs. IDIX: 27.84 )
IDIX' s 10-Year Price/Net Cash Range
Min: 2.78   Max: 343
Current: 27.84

2.78
343
Price/Net Current Asset Value 27.53
IDIX's Price/Net Current Asset Value is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 45.54 vs. IDIX: 27.53 )
IDIX' s 10-Year Price/Net Current Asset Value Range
Min: 2.78   Max: 83.67
Current: 27.53

2.78
83.67
Price/Tangible Book 24.26
IDIX's Price/Tangible Book is ranked higher than
63% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. IDIX: 24.26 )
IDIX' s 10-Year Price/Tangible Book Range
Min: 1.84   Max: 38.05
Current: 24.26

1.84
38.05
Forward Rate of Return (Yacktman) -4.47
IDIX's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. IDIX: -4.47 )
IDIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.3   Max: -32
Current: -4.47

-50.3
-32

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NO9.Germany
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's main research and development focus is on the treatment of hepatitis C virus, or HCV. HCV is a cause of liver disease. The Company is currently developing nucleoside/nucleotide polymerase inhibitors and NS5A inhibitors to inhibit HCV replication. The Company has developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1, or HIV, and acquired immune deficiency syndrome, or AIDS, for use in combination therapy. In 2008, it successfully completed a proof-of-concept clinical trial of IDX899 in treatment-naïve HIV-infected patients. In February 2009, it licensed its NNRTI compounds to GlaxoSmithKline. In collaboration with Novartis, it developed telbivudine (Tyzeka/Sebivo) through commercialization for the treatment of patients with HBV. In October 2006, the FDA approved Tyzeka in the United States and Sebivo was approved in 2007 in more than 50 countries outside the United States, including major Asian countries and several countries included in the European Union. Companies the compete with in the HCV market include Abbott Laboratories, Boehringer Ingelheim International GmbH, F. Hoffman-LaRoche & Co., Johnson & Johnson, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis, Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc., and Presidio Pharmaceuticals, Inc. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposing of hazardous materials and waste products, including certain regulations promulgated by the U.S. Environmental Protection Agency, or EPA.
» More Articles for IDIX

Headlines

Articles On GuruFocus.com
Prem Watsa Buys 4 New Stocks Aug 13 2014 
Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
The Peril of Being a Copycat Jun 26 2014 
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
2013 - Mistakes of Commission,Omission & Confusion Feb 12 2014 
Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
Seth Klarman Continues Aggressively Buying Drug Company, Soros Adds Mercury Systems Nov 05 2013 
The Philosophy and Value of Gurufocus Sep 08 2013 
Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracle May 14 2013 

More From Other Websites
Biotech targets: Cramer's quality candidates Sep 11 2014
UPDATE: Deutsche Bank Initiates Coverage On Merck Aug 27 2014
Achillion Pharmaceuticals Up On Buyout Rumors Aug 18 2014
Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower Aug 05 2014
IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Aug 05 2014
Q2 2014 Idenix Pharmaceuticals, Inc. Earnings Release - Time Not Supplied Aug 04 2014
IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 31 2014
IDENIX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2014 Financial Results Jul 31 2014
Merck, Pfizer Ramping R&D After Q2 Earnings Beat Jul 29 2014
Merck 2Q profit more than doubles Jul 29 2014
Every Which Way But Short Jul 24 2014
[video] Cramer's Stop Trading: Yellen effect Jul 16 2014
A Pre-Earnings Update On Gilead Jul 10 2014
Seth Klarman Is Top-Performing Guru for First Half 2014 Jul 05 2014
A Primer On The Hepatitis C Market Jul 03 2014
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
Idenix (IDIX) is in Overbought Territory: What's Next? Jul 03 2014
What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? Jun 27 2014
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly Jun 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK